![Teva to Settle US Opioid Lawsuits for $4.35 Billion | The Jewish Press - JewishPress.com | David Israel | 28 Tammuz 5782 – July 27, 2022 | JewishPress.com Teva to Settle US Opioid Lawsuits for $4.35 Billion | The Jewish Press - JewishPress.com | David Israel | 28 Tammuz 5782 – July 27, 2022 | JewishPress.com](https://www.jewishpress.com/wp-content/uploads/2022/07/Teva-Pharmaceutical-Industries-CEO-Kare-Schultz-speaks-at-a-press-conference-at-the-Tel-Aviv-Stock-Exchange-February-19-2020..jpg)
Teva to Settle US Opioid Lawsuits for $4.35 Billion | The Jewish Press - JewishPress.com | David Israel | 28 Tammuz 5782 – July 27, 2022 | JewishPress.com
![Shlomo Yanai, Teva's president and chief executive, addresses the media during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher quarterly net Shlomo Yanai, Teva's president and chief executive, addresses the media during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher quarterly net](https://c8.alamy.com/comp/2D1M57M/shlomo-yanai-tevas-president-and-chief-executive-addresses-the-media-during-a-news-conference-in-tel-aviv-july-27-2010-teva-pharmaceutical-industries-the-worlds-largest-generic-drugmaker-reported-higher-quarterly-net-profit-on-tuesday-boosted-by-sales-of-generic-medicines-and-its-own-branded-multiple-sclerosis-treatment-copaxone-reutersnir-elias-israel-tags-business-2D1M57M.jpg)
Shlomo Yanai, Teva's president and chief executive, addresses the media during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher quarterly net
![TEVA PHARMA @ ANZAN Introducing Teva Pharma to the ANZAN conference in Auckland requires a lot of 'presence… | Experiential marketing, Experiential, Branding design TEVA PHARMA @ ANZAN Introducing Teva Pharma to the ANZAN conference in Auckland requires a lot of 'presence… | Experiential marketing, Experiential, Branding design](https://i.pinimg.com/736x/fa/d7/e9/fad7e9d456fb75d4dc1a2540bcb9af95--auckland-exhibition.jpg)
TEVA PHARMA @ ANZAN Introducing Teva Pharma to the ANZAN conference in Auckland requires a lot of 'presence… | Experiential marketing, Experiential, Branding design
![Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates, Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates,](https://c8.alamy.com/comp/2CX4Y3N/teva-pharmaceutical-industries-new-ceo-jeremy-levin-speaks-during-a-news-conference-in-tel-aviv-may-9-2012-teva-pharmaceutical-industries-posted-a-40-percent-jump-in-quarterly-profit-that-beat-estimates-boosted-by-robust-sales-of-its-own-branded-products-and-generic-medicines-in-the-united-states-reutersnir-elias-israel-tags-business-health-2CX4Y3N.jpg)
Teva Pharmaceutical Industries' new CEO Jeremy Levin speaks during a news conference in Tel Aviv May 9, 2012. Teva Pharmaceutical Industries posted a 40 percent jump in quarterly profit that beat estimates,
![Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 | Business Wire Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 | Business Wire](https://mms.businesswire.com/media/20221006005712/en/739014/23/teva_RGB_JPEG.jpg)
Teva to Host Conference Call to Discuss Third Quarter 2022 Financial Results at 8 a.m. ET on November 3, 2022 | Business Wire
![Teva Pharmaceutical CEO Shlomo Yanai delivers a press conference in Cologne, Germany, 18 March 2010. German generics producer Ratiopharm is sold to world's leading generic producer Teva Pharmaceutical at 3.625 billion euro. Teva Pharmaceutical CEO Shlomo Yanai delivers a press conference in Cologne, Germany, 18 March 2010. German generics producer Ratiopharm is sold to world's leading generic producer Teva Pharmaceutical at 3.625 billion euro.](https://c8.alamy.com/comp/D56P1T/teva-pharmaceutical-ceo-shlomo-yanai-delivers-a-press-conference-in-D56P1T.jpg)